

NIH BIOGRAPHICAL SKETCH COMMON FORM

Name: Vanderbilt, Douglas

Persistent Identifier (PID) of the Senior/Key Person: <https://orcid.org/0000-0003-2038-0808>

Position Title: Professor of Pediatrics

Organization and Location: Stanford School of Medicine, Stanford, California, United States

PROFESSIONAL PREPARATION

INSTITUTION AND LOCATION	DEGREE	Start Date	Completion Date	FIELD OF STUDY
USC Marshall School of Business, Los Angeles , California, United States	Master of Business Administration (MBA)	07/2019	12/2023	Business
USC Keck School of Medicine, Los Angeles , California, United States	Master of Science (MS)	07/2013	05/2015	Clinical and Translational Investigations
Zero to Three, Washington D.C., District of Columbia, United States	Other training	06/2007	06/2009	Early Childhood Policy Training
Shriver Center, Waltham, Massachusetts, United States	Other training	08/2004	05/2005	Leadership Education in Neurodevelopmental Disabilities
Boston University School of Medicine, Boston, Massachusetts, United States	Fellow	07/2002	06/2005	Developmental-Behavioral Pediatrics
UCLA Children's Hospital, Los Angeles, California, United States	Resident	07/1999	06/2002	Pediatrics
University of Tennessee, Memphis College of Medicine, Memphis, California, United States	DOCTOR OF MEDICINE	07/1995	06/1999	Medicine
Stanford University, Stanford, California, United States	BACHELOR OF ARTS	09/1991	06/1995	Psychology- Health and Development Track

Appointments and Positions

2026 - present	Professor of Pediatrics, Stanford School of Medicine, Stanford, California, United States
2025 - present	DC:0-5 Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood Revision Project Steering Committee, Zero to Three, Zero to Three, Washington D.C., District of Columbia, United States
2023 - present	Las Madrinas Endowed Chair of Developmental-Behavioral Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, United States
2022 - present	Founding Director, Division of Developmental-Behavioral Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, United States
2021 - present	Clinical Professor Occupational Science/Therapy, USC Ostrow School of Dentistry, Los Angeles, California, United States
2018 - 2022	Permanent Member- Biobehavioral and Behavioral Sciences (CHHD-H) Study Section, NICHD, Bethesda, Maryland, United States
2015 - 2022	Associate Director, USC University Center for Excellence in Developmental Disabilities, Los Angeles, California, United States
2013 - present	Program Director, MCHB Developmental-Behavioral Pediatrics Training Program , Los Angeles, California, United States

2013 - 2021	Executive Committee Member, Council on Early Childhood, American Academy of Pediatrics, Chicago, Illinois, United States
2012 - 2020	Associate Professor of Clinical Pediatrics, USC Keck School of Medicine, Los Angeles, California, United States
2011 - present	Program Director, California Leadership Education in Neurodevelopmental Disabilities Training Program , Los Angeles, California, United States
2010 - present	Medical Director, CHLA High Risk Infant Follow-up Clinic, Los Angeles, California, United States
2008 - present	Program Director, CHLA Developmental-Behavioral Pediatrics Fellowship, Los Angeles, California, United States
2007 - 2012	Assistant Professor of Clinical Pediatrics, USC Keck School of Medicine, Los Angeles, California, United States
2005 - 2007	Assistant Professor of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, United States
2003 - 2004	Instructor in Pediatrics, Boston University School of Medicine , Boston, Massachusetts, United States

Products

Products Closely Related to the Proposed Project

1. Ke JC, Hayati Rezvan P, Vanderbilt D, Mirzaian CB, Deavenport-Saman A, Smith BA. Similar early intervention referral rates following in-person administration of the Bayley Scales of Infant and Toddler Development, 4th Edition versus Telehealth Administration of the Developmental Assessment in Young Children, 2nd Edition in the high-risk infant population. Early Hum Dev. 2024 Mar;190:105971. PubMed Central PMCID: [PMC12412277](#).
2. Mirzaian CB, Ghadiali T, Vestal N, Song A, Vanderbilt D, Lakshmanan A. Rates of connection to early intervention from the neonatal intensive care unit in a high risk infant follow-up program. J Perinatol. 2022 Oct;42(10):1412-1414. PubMed PMID: [35589971](#).
3. Nghiem N, Martes Gomez M, Vu MH, Deavenport-Saman A, Vanderbilt D, Lakshmanan A, Wang S, Boodaghian A, Mirzaian CB. Association of maternal primary language with neurodevelopmental outcomes in high-risk infants. J Perinatol. 2025 Dec;45(12):1722-1728. PubMed Central PMCID: [PMC12717000](#).
4. Lakshmanan A, Sunshine I, Escobar CM, Kipke M, Vanderbilt D, Friedlich PS, Mirzaian CB. Connecting to Early Intervention Services After Neonatal Intensive Care Unit Discharge in a Medicaid Sample. Acad Pediatr. 2022 Mar;22(2):253-262. PubMed Central PMCID: [PMC8901461](#).
5. Yeo EN, Young ND, Cleveland JC 3rd, Simon TD, Vanderbilt DL, Espinoza J, Mirzaian CB, Alderete TL. High-Risk Infant Developmental Outcome Is Associated with Medical Complexity and Neighborhood Opportunity. J Pediatr. 2025 Apr;279:114433. PubMed Central PMCID: [PMC11903178](#).

Other Significant Products Highlighting Contributions to Science

1. Barbaresi W, Cacia J, Friedman S, Fussell J, Hansen R, Hofer J, Roizen N, Stein REK, Vanderbilt D, Sideridis G. Clinician Diagnostic Certainty and the Role of the Autism Diagnostic Observation Schedule in Autism Spectrum Disorder Diagnosis in Young Children. JAMA Pediatr. 2022 Dec 1;176(12):1233-1241. PubMed Central PMCID: [PMC9577880](#).
2. Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Loe IM, Mittal S, Tulio S, Vanderbilt D, Blum NJ. α 2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder. JAMA. 2021 May 25;325(20):2067-2075. PubMed Central PMCID: [PMC8097628](#).
3. Neel ML, Bora S, Brachio SS, Duncan A, Vanderbilt D, Benninger K, Kendrick-Allwood S, Maitre NL. Challenges and Opportunities in High-Risk Infant Follow-Up: Progress from the 2022 Networking Session at the Pediatric Academic Societies. J Pediatr. 2024 Jul;270:113971. PubMed PMID: [38479638](#).
4. Dusing SC, Harbourne RT, Hsu LY, Koziol NA, Kretch K, Sargent B, Jensen-Willett S, McCoy SW, Vanderbilt DL. The SIT-PT Trial Protocol: A Dose-Matched Randomized Clinical Trial Comparing 2 Physical Therapist Interventions for Infants and Toddlers With Cerebral Palsy. Phys Ther. 2022 Jul 4;102(7) PubMed Central PMCID: [PMC9291380](#).
5. Vanderbilt DL, Schrager SM, Llanes A, Hamilton A, Seri I, Chmait RH. Predictors of 2-year cognitive performance after laser surgery for twin-twin transfusion syndrome. Am J Obstet Gynecol. 2014 Oct;211(4):388.e1-7. PubMed Central PMCID: [PMC4175130](#).

Certification:

I certify that the information provided is current, accurate, and complete. This includes, but is not limited to, information related to current, pending, and other support (both foreign and domestic) as defined in 42 U.S.C. § 6605.

In accordance with Section 10632 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19232), each individual identified as a senior/key person must certify that they are not a party to a malign foreign talent recruitment program.

Research Security Training Requirement for Federal Award Personnel: In accordance with Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19234), each individual identified as a senior/key person must certify that they have completed the requisite research security training that meets the requirements specified in Item 2 of Important Notice No. 149 within 12 months prior to proposal submission.

Misrepresentations and/or omissions may be subject to prosecution and liability pursuant to, but not limited to, 18 U.S.C. §§287, 1001, 1031 and 31 U.S.C. §§3729-3733 and 3802.

Certified by Vanderbilt, Douglas in SciENCv on 2026-09-11 19:22:18

NIH BIOGRAPHICAL SKETCH SUPPLEMENT

Name: Vanderbilt, Douglas

Persistent Identifier (PID) of the Senior/Key Person: <https://orcid.org/0000-0003-2038-0808>

Position Title: Professor of Pediatrics

Organization and Location: Stanford School of Medicine, Stanford, California, United States

Personal Statement

In this R01 grant as Co-I, I will provide expertise and support with infant development, Developmental-Behavioral Pediatrics (DBP), and the understanding of risk factors to infant outcomes in light of health outcomes. My role will be to provide expertise on neonatal follow-through and health services research with Drs. Lakshmanan, Mirzaian and her team. I will also provide assistance with and oversight of data acquisition and consult on data analysis, interpretation, and dissemination. I will also participate in project meetings and dissemination of results in scientific journals. I am qualified for this role based on my previous work in the neurodevelopmental outcomes of medically high-risk infant outcomes, extensive clinical experience in diagnosing and treating NICU graduates, and publications in the field of high-risk infant outcomes in DBP. I am a Professor of Clinical Pediatrics and Occupational Science/Occupational Therapy at CHLA and USC Keck School of Medicine. I have extensive experience in evaluating conceptual models that incorporate a translational and relational approach to understand neurodevelopmental outcome of high-risk children. Clinically I oversee the NICU follow up clinic from which recruitment will occur. I am a site PI for the Developmental-Behavioral Pediatrics Research Network (DBPnet), which is the only national professional society devoted exclusively to DBP disorders. I attained a KL2 Mentored Career Development Award to study the outcomes of medically high-risk infants and have been an author in over 100 manuscripts, policy statements, editorials, and chapters. I have been funded on 5 NIH grants as a Co-I on a NIBIB R01 (PI: Lepore) study of neuroimaging and neurodevelopmental outcomes in premature infants, a NIDA R34 (PI: Levitt) study on substance exposed infants focusing on dyadic interactions, a NICHD R01 (PI: Smith) study on development of arm reaching in a high risk sample, and a NICHD R01 (PI: Dusing) clinical trial on an intervention for cerebral palsy and as the neurodevelopmental examination director for the NINDS HEAL Trial (PI: Wu) at the CHLA site and have been continuously funded by the MCHB since 2011. I have research collaborations with interdisciplinary teams of researchers around social determinants in health outcomes and have extensive research collaborations with Drs. Mirzaian and Lakshmanan.

Honors

2020	Membership, American Pediatric Society
2013	Membership, Society of Pediatric Research
1999	Membership, Alpha Omega Alpha Honor Medical Society

Contributions to Science

1. Risk Factors to Development Among High Risk Infants. I have used a population of genetically identical twins who have had unequal sharing of blood through vascular communications and other high risk infants. These unique high risk infant outcomes have not been extensively studied nor has their risk factors been examined. My contribution explores these risk factors and correlates that are being used clinically today in our counseling of families.
2. Social Complexity in High Risk Infants Outcomes. I have collaborated on examining the social determinants of those born at medical risk.
3. Behavioral Consequences of High Risk Infants. I have contributed to the literature by providing a context for poorer premature and other high risk infant birth outcomes. These evidence-based reviews and recommendations provide a guide for clinicians to understand the risks and outcomes to identify in these infants and strategies for intervention.
4. Caregiver Distress with High Risk Infants. There is emerging literature acknowledging the traumatic stress that is elicited in caregivers who have had infants that required intensive care. These publications identify the increased depression and posttraumatic stress found in a urban population with caregivers who had infants in the neonatal intensive care unit. The later publications stressed the importance of screening for these symptoms to prevent infant-caregiver relationship problems such as

breastfeeding bonding. This work sets the standard for identification and screening for these high risk infants.

5. Health Outcomes in Developmental-Behavioral Pediatrics. I have engaged in team science around DBP topics in ADHD and Autism with a special emphasis on health differences in outcome.

Certification:

I certify that the information provided is current, accurate, and complete. This includes, but is not limited to, information related to current, pending, and other support (both foreign and domestic) as defined in 42 U.S.C. § 6605.

In accordance with Section 10632 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19232), each individual identified as a senior/key person must certify that they are not a party to a malign foreign talent recruitment program.

Research Security Training Requirement for Federal Award Personnel: In accordance with Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19234), each individual identified as a senior/key person must certify that they have completed the requisite research security training that meets the requirements specified in Item 2 of Important Notice No. 149 within 12 months prior to proposal submission.

Misrepresentations and/or omissions may be subject to prosecution and liability pursuant to, but not limited to, 18 U.S.C. §§287, 1001, 1031 and 31 U.S.C. §§3729-3733 and 3802.

Certified by Vanderbilt, Douglas in SciENCv on 2026-09-11 19:22:18